Sirius Therapeutics Secures $50M Series B Boost to Fuel PAQ Therapeutics’ ATTEC Innovation Revolution

In an exciting development for the field of biotechnology, PAQ Therapeutics—known for its pioneering work in harnessing autophagy for therapeutic purposes—has announced a landmark funding round of $50 million. This significant influx of capital marks a pivotal step forward in PAQ’s mission to revolutionize drug discovery and development. As a company at the forefront of a new era in medicine, PAQ Therapeutics employs its innovative ATTEC (autophagosome-tethering compound) technology to develop a novel class of small molecule degraders. These compounds have the unique ability to bind to a diverse array of substrates—including proteins, aggregates, lipids, organelles, and even pathogens—thus leveraging the body’s natural cellular degradation process for the treatment of various diseases. The raised funds will primarily support the advancement of research and development efforts, with a focus on expanding the preclinical pipeline and initiating early-stage clinical trials. By further investigating and optimizing their ATTEC technology, PAQ Therapeutics aims to address some of the most challenging aspects of disease pathology that have historically been difficult to target with traditional therapeutics. Additionally, the capital infusion will enable PAQ to form key strategic partnerships, enhance their manufacturing capabilities, and accelerate the translation of their cutting-edge science from the laboratory to the clinic. This milestone investment not only validates the scientific rigor behind PAQ’s approach but also underscores the growing confidence in the potential for autophagy modulation to transform patient outcomes across a spectrum of diseases. As PAQ Therapeutics embarks on this exciting new chapter, the biotechnology community and patients alike can look forward to groundbreaking advancements in therapeutic strategies that promise to redefine the future of healthcare.